Fig. 2From: Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control studyStudy procedures. Overview of the TransBioLine study recruitment pathway for suspected drug-induced liver injury (DILI) casesBack to article page